Echosens and Boehringer Ingelheim have expanded their collaboration aimed at expediting progress in MASH diagnosis and care.

Noninvasive alternatives are beginning to become more accessible, however, and Echosens, the developer of one such offering, is on a quest to use its technology to vastly increase NASH screening.

WALTHAM, Mass. & NASHVILLE, Tenn.--(BUSINESS WIRE)--Echosens, a high-technology company offering the FibroScan family of products, announces its collaboration with MetaPhy Health to support turn ...

WALTHAM, Mass. & FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Echosens North America, a high-technology company offering the FibroScan ® portfolio of solutions, and ChronWell, a digital health and ...

Founded in 2001 in France, Echosens is a world-leading high-tech company specializing in non-invasive diagnostic products and services for hepatology. It produces FibroScan®, which is an advanced ...

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting more than 250 million people worldwide—Echosens, ...

PARIS, Aug. 26, 2024 /PRNewswire/ -- Echosens is thrilled to unveil the inaugural Liver Health Super Shaper Award, a heartfelt initiative designed to celebrate the extraordinary medical ...

DIMO Healthcare, a leader in the Sri Lankan healthcare sector, has introduced the country’s first Echosens FibroScan® Expert ...

WESTBOROUGH, Mass., Dec. 9, 2024 /PRNewswire/ -- Echosens, the leader in liver health, is proud to be recognized as one of the 2024 Top Places to Work in Massachusetts, earning a spot among the ...

By combining their diagnostic and therapeutic expertise, Echosens and Boehringer Ingelheim aim to help close persistent gaps ...